May 1, 2024

TechNewsInsight

Technology/Tech News – Get all the latest news on Technology, Gadgets with reviews, prices, features, highlights and specificatio

The first injections of Novavax could start in France “at the beginning of February”

This vaccine has the peculiarity of not using messenger RNA technology, unlike those of Pfizer-BioNTech and Moderna.

Article by

published

to update

reading time : 1 minute.

This is the fifth vaccine to be approved in the European Union. The first injections of the anti-Covid-19 vaccine from Novavax could happen in France At the beginning of FebruaryThe Ministry of Health announced Thursday, January 6th. This vaccine was approved on December 20 in the European Union and its use in France is still subject to the opinion of the High Authority for Health (HAS).

This opinion is waiting “in the coming days”According to the Ministry of Health. According to the Ministry, France should receive 3.2 million doses of this vaccine in the first trimester, put up an option for 3.2 million more doses In the second chapter. The first shipments are expected At the end of January According to the ministry, but “Signals indicate potential delays.”.

This vaccine has the peculiarity of not using messenger RNA technology, unlike those in Pfizer-Biwantech and Moderna (the two dominant operators today in France after the gradual abandonment of AstraZeneca and Janssen).

Sold under the name Nuvaxovid, this vaccine made by the American laboratory Novavax is a vaccine called “subunit” : Contains a component of the virus (not the entire virus like more traditional vaccines), which is inserted into the body to stimulate an immune response.

This technology builds on vaccines that have been around for several decades, such as those against whooping cough, meningococcal meningitis, and hepatitis B. mRNA is brand new.

See also  Hyundai develops V2X technology to stabilize the power grid

“may be [ce vaccin] Be a strong encouragement to the unvaccinated or those who haven’t remembered! “, had hoped that the President of the European Commission, Ursula von der Leyen, during its approval in the European Union.